Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant

Despite significant strides in pre-emptive antiviral treatment of cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) and a corresponding reduction in CMV disease rates, toxicity from these therapies remains unacceptably high. New antivirals are urgently needed for CMV management. However, because of low CMV disease rates, clinical trials for new therapeutics and vaccines require large sample sizes to show clinical benefit.

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Elizabeth R. Duke, Peter B. Gilbert, Terry L. Stevens-Ayers, Jonathan L. Golob, Nicole Cossrow, Morgan A. Marks, Hong Wan, T. Christopher Mast, Meei-Li W. Huang, Keith R. Jerome, Lawrence Corey, Joshua T. Schiffer, Michael J. Boeckh Source Type: research